FOLH1 and prostate carcinoma: The use of PSMA (prostate-specific membrane antigen) targeted radiopharmaceuticals overcomes this, offering a more personalised treatment, targeting as it does the PSMA receptor on the cell surface of prostate cancer cells directly.